Phase I and Pharmacokinetics Study of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the dose limiting toxicities (DLTs)and the maximum tolerated dose (MTD) of the combination of Lapatinib and Sorafenib.
0ne year
No
Armando Santoro, MD
Principal Investigator
Istituto Clinico Humanitas
Italy: Ministry of Health
ONC-2008-005
NCT00984425
September 2009
September 2010
Name | Location |
---|